glp 1 hormone imbalance GLP-1 receptor agonists and next-generation metabolic therapies in chronic kidney disease Science Behind GLP 1 GIP

A longitudinal study of urea cycle disorders

CagriSema, as of mid-2026, has completed its Phase 3a REDEFINE program but is not approved by the FDA, the EMA, or any other regulator, and its benefitrisk profile is still under review

Too little water and the dose falls to a sliver of a unit that is easy to misread

Radiation sickness and radiation safety: radiation, radioactive substances or because of leukopenia caused by anticancer drugs and other symptoms can play a protective effect

Environmental medicine doctors who treat firefighters report that just one month of inhalable glutathione treatment can reduce or even eliminate respiratory symptoms associated with long-term occupational exposure to smoke

PPARA is a ligand-activated nuclear receptor highly expressed in the liver parenchymal cell population i.e